Close Menu

NEW YORK – California-based A2 Biotherapeutics will begin clinical development of its T-cell module platform, called Tmod, after raising $71.5 million in funding.

Existing investors, including The Column Group, Vida Ventures, Samsara BioCapita, and Nextech Invest, participated in the Series B funding round, along with new investors Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents), and Hartford HealthCare Endowment.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Nov
03

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Nov
09
Sponsored by
Akoya Biosciences

Most recent single-cell and spatial biology studies have focused on the network of interactions between different cell types and their spatial context.